بررسی ، آینده نگری و پیشرفتهای مهم در درمان و جلوگیری از گسترش بیماریCovid19(از منظرحقوق بشر دوستانه)
  •   آرشیو : نسخه تابستان 1400
  •   شناسه دیجیتال (DOI) : 2DOI
  •   شناسه دیجیتال (DOR) : DOR
  •   شناسه دیجیتال (ISC) : ISC
  •   کد پذیرش : joce14005306714
  •   موضوع : حقوق جزا
  • نویسنده/گان : مریم رحیمی
  •   زبان : فارسی
  •   نوع مقاله : پژوهشی
  •   چکیده مقاله به فارسی : شیوع کووید 19 یک سندرم حاد تنفسی است که مهم‌ترین روش برای تشخیص آن PCR است. انجمن پزشکی کره برای تست آزمایشگاهی و مراکز پیشگیری و کنترل دستورالعمل هایی را برای تشخیص COVID-19 در آزمایشگاه های بالینی کره ارائه می دهد. سازمان بهداشت جهانی، اخیراً پاندمی شدن این بیماری را اعلام کرد. ویروس SARS-CoV-2 که از لحاظ ژنتیکی مشابهARS-Cov و سندرم حاد تنفسی خاور میانه (MERS) است، ویروسی پوشش‌دار، دارای یک RNA تک‌رشته‌ای شامل 29891 نوکلئوتید و دارای 12 ژن برای سنتز پروتئین‌های ساختاری و غیرساختاری ویروس است و به لحاظ پروتئینی، بسیار مشابه پروتئین‌های SARS-CoV و MERS-CoV می‌باشد. در حال حاضر، درمان ثابت و مشخصی برای این بیماری وجود ندارد. به همین دلیل مقالات موجود در مورد بیماری Coronavirus 2019 کرونا از نظر اپیدمیولوژی، پاتوفیزیولوژی، تشخیص و درمان بررسی شده است. هدف از این پژوهش، مروری بر تجربه‌های جهانی در این زمینه و جمع‌آوری این اقدامات و سیاست‌گذاری‌ها و جمع‌بندی و به اشتراک گذاشتن آن‌ها و ارائه پیشنهاد‌های سیاستی نوآورانه، باهدف کمک به کاهش اثرات پاندمی کرونا در آموزش‌ عالی مهارتی است در این بررسی، پایگاه داده‌های MEDLINE ، SCIENCEDIRECT و Scopus برای مقالات مربوطه جستجو شدند.یافته‌ها از زمان پیدایش این بیماری، دانشمندان زیادی علاقه‌مند به کشف راهکاری مناسب برای مهار آن می‌باشند. در این مقاله، تصویری از یافته‌های فعلی در مورد اپیدمیولوژی، ویژگی‌های بالینی، تشخیص، مدیریت و پیشگیری از COVID-19 ارائه شده است. نتیجه‌گیری همه‌گیری COVID-19 نشان‌دهنده بزرگ‌ترین بحران بهداشت عمومی جهانی است. آزمایش‌های بالینی که برای بررسی روش‌های درمانی بالقوه برای COVID-19 آغاز شده است بسیار بالاست ولی متأسفانه تاکنون منجر به تولید داروی مؤثری نشده است. بنابراین برای مقابله با این ویروس، اقدامات اضطراری پیشگیرانه و هماهنگ بین همه کشورها مورد نیاز است.
  •   لیست منابع : منابع:
    [1] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020; 92: 401–402.
    [2] Huang C, Wang Y, Li Z, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
    [3] World Health Organization Director-General’s Opening Remarks at the Media Briefing on COVID-19–11 March 2020. Available online: https://www.who.int/dg/speeches/detail/whodirector-general-s-openingremarks- at-the-mediabriefing-on-covid-19---11-march-2020 (accessed on 11 March 2020).
    [4] Perlman S, Netland J. Coronaviruses post-SARS: Update on replication and pathogenesis. Nat Rev Microbiol. 2009; 7: 439–450.
    [5] Lu, R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020; 395: 565–574.
    [6] Phan T. Novel coronavirus: From discovery to clinical diagnostics. Infect. Genet Evol. 2020; 79.
    [7] World Health Organization Novel Coronavirus (2019nCoV), Situation Report 1. 21 January 2020. Available online: https://www.who.int/docs/defaultsource/coronaviruse/situation-reports/20200121-sitrep1-2019-ncov.pdf (accessed on 25 March 2020).
    [8] Hsu LY, Chia PY, Lim JF. The Novel coronavirus (SARSCoV-2) epidemic Ann Acad Med Singap. 2020; 49: 3-14.
    [9] World Health Organization Novel Coronavirus (2019nCoV) Situation Report 21 May 2020. Available online: https://www.who.int/emergencies/diseases/novelcoronavirus-2019
    [10] Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. Antivir. Res. 2018; 149: 58–74.
    [11] Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020; 5: 562– 569.
    [12] Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020.
    [13] Cheepsattayakorn A, Cheepsattayakorn R. Proximal origin and phylogenetic analysis of COVID-19 (2019nCoV or SARS-CoV-2). EC Microbiol 2020.
    [14] Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017; 39: 529–39.
    [15] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506.
    [16] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8: 420–2.
    [17] Luo W, Yu H, Gou J, Li X, Sun Y, Li J, Liu L. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints 2020, 202002040
    [18] Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Chinese Journal of Burns, 2020; 36. [19] Bennardo F, Bu one C, Giudice A. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws. Oral Oncol. 2020.
    [20] Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol. 2018, 10.
    [21] Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J Glob Antimicrob Resist. 2020; 21: 22–27.
    [22] Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, Sun J, Chang C. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J. Autoimmun. 2020.
    [23] Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology 2020.
    [24] Li Y, Xia L. Coronavirus disease 2019 (COVID-19): Role of chest CT in diagnosis and management. AJR Am J Roentgenol. 2020;214:1280-1286
    [25] Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, Pan I, Shi LB, Wang DC, Mei J. et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology 2020.
    [26] World Health Organization Covid 19 Infection. Available online:https://www.who.int/emergencies/diseases/ novel-coronavirus-2019 (accessed on 31 March 2020).
    [27] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020.
    [28] Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020.
    [29] Lagier JC, Colson P, Tissot Dupont H, Salomon J, Doudier B, Aubry C, Gouriet F, Baron S, Dudouet P, Flores R. et al. Testing the repatriated for SARS-Cov2: Should laboratory-based quarantine replace traditional quarantine? Travel Med Infect Dis. 2020.
    [30] Wang H, Wang S, Yu K. COVID-19 infection epidemic: The medical management strategies in Heilongjiang Province, China. Crit Care 2020; 24: 107.
    [31] Chan KW, Wong VT, Tang SCW. COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 2020; 13: 1–26.
    [32] Sanders JM, Monogue ML, Jodlowski T Z, Cutrell J B, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020.
    [33] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395; 473–475.
    [34] Francesco Di G, Damiano P, Claudia M, Mario A, Vincenzo R, Nicola V, Lee S. Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. Int J Environ Res. Public Health 2020; 17: 2690
    [35] Chien M, Anderson TK, Jockusch S, et al. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase. bioRxiv.2020.
    [36] Ju J. LiX, Kumar S, et al. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase.BioRxiv.2020.
    [37] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30: 269–271.
    [38] Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020; 9441: 30390–30397.
    [39] Biggioggero, M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: An evidence-based review and patient selection. Drug Des Dev Ther. 2018; 13: 57–70.
    [40] Lim J, Jeon S, Shin HY. The author’s response: Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: The application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative
    [41] Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–A review of immune changes in patients with viral pneumonia. Emerg. Microbes Infect. 2020; 9: 727-732
    [42] European Medicines Agency. EMA Gives Advice on the Use of Non-Steroidal Anti-Inflammatories for COVID-19. Available online: https://www.ema.europa.eu/en/news/emagivesadvice-use-non-steroidal-antiinflammatories- covid-19 (accessed on 25 March 2020).
    [43] Watkins, J. Preventing a covid-19 pandemic. BMJ 2020; 368.
  •   کلمات کلیدی به فارسی : کرونا، مهارت ، پاندمی ، پیشگیری آموزش عالی
  •   چکیده مقاله به انگلیسی : Prevalence of Covid 19 is an acute respiratory syndrome whose most important method for diagnosis is PCR. The Korean Medical Association for Laboratory Testing and Prevention and Control Centers provides guidelines for the diagnosis of COVID-19 in Korean clinical laboratories. The World Health Organization recently declared the disease a pandemic. The SARS-CoV-2 virus, which is genetically similar to ARS-Cov and the Middle East Acute Respiratory Syndrome (MERS), is a coated virus with a single-stranded RNA containing 29891 nucleotides and 12 genes for the synthesis of structural and non-structural proteins of the virus. Is very similar to SARS-CoV and MERS-CoV proteins. Currently, there is no definitive treatment for this disease. For this reason, the existing articles on Coronavirus 2019 Corona have been reviewed in terms of epidemiology, pathophysiology, diagnosis and treatment. The purpose of this study is to review global experiences in this field and to collect these actions and policies and to summarize and share them and provide innovative policy proposals, in order to help reduce the effects of the Corona Pandemic in higher education. In this review, MEDLINE , SCIENCEDIRECT and Scopus were searched for related articles. Findings Since the emergence of this disease, many scientists have been interested in discovering a suitable solution to control it. This paper provides an overview of current findings on the epidemiology, clinical features, diagnosis, management and prevention of COVID-19. Conclusion The COVID-19 epidemic represents the greatest global public health crisis. The clinical trials that have begun to examine potential treatments for COVID-19 are very high, but unfortunately have not yet led to the production of an effective drug. Therefore, to prevent this virus, preventive and coordinated emergency measures are needed between all countries.
  •   کلمات کلیدی به انگلیسی : Corona, Skills, Pandemic, Higher Education Prevention
  •  صفحات : 70-83
  •   دانلود فایل ( 462.12 KB )